Axsome Therapeutics

Axsome Therapeutics

AXSM· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +115.9% in FY2025

Herriot Tabuteau, M.D. is the CEO of Axsome Therapeutics and was paid $10.3M in FY2025 (Dec), down 1%.

Pay$100 in the stock at the end of FY20 → $224
CEO pay is from each Axsome Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1Herriot Tabuteau, M.D.FY2025
  2. 2Mark Jacobson, M.A.FY2025
  3. 3Nick Pizzie, C.P.A., M.B.A.FY2025
  4. 4Hunter Murdock, Esq.FY2025
  5. 5Ari Maizel, M.B.A.FY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Axsome Therapeutics paid its 5 named executives $24.6M in total in FY2025 (Dec). CEO Herriot Tabuteau, M.D. was paid $10.3M of that.

Name
Herriot Tabuteau, M.D.Chief Executive Officer, President and Chairman of the Board
Mark Jacobson, M.A.Chief Operating Officer
Nick Pizzie, C.P.A., M.B.A.Chief Financial Officer
Hunter Murdock, Esq.General Counsel
Ari Maizel, M.B.A.Chief Commercial Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers16

See all

The FY2025 (Dec) proxy of Axsome Therapeutics names 16 peer companies for pay. Pay versus performance data of Axsome Therapeutics for that year is not on file, so it has no rank.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Activity

Filings6

See all
Proxy statementDEF 14AApr 24, 2026FY2025
Annual report10-KFeb 23, 2026FY2025
Proxy statementDEF 14AApr 25, 2025FY2024
Annual report10-KFeb 18, 2025FY2024
Proxy statementDEF 14AApr 26, 2024FY2023
Annual report10-KFeb 23, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data